These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17641998)

  • 1. Pricing and Reimbursement Conference--VisionGain's Fifth Annual Meeting.
    Cleverley J
    IDrugs; 2007 Jun; 10(6):373-6. PubMed ID: 17641998
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK.
    Ogbighele E
    IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicines pricing singled out.
    Buchanan E
    S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
    [No Abstract]   [Full Text] [Related]  

  • 4. European pharmaceutical pricing and reimbursement conference.
    Ehreth J; Williams D
    Expert Rev Pharmacoecon Outcomes Res; 2009 Feb; 9(1):37-9. PubMed ID: 19371177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 6. Pricing medicines: theory and practice, challenges and opportunities.
    Gregson N; Sparrowhawk K; Mauskopf J; Paul J
    Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem.
    Hollis A; Grootendorst P
    Healthc Policy; 2015 Aug; 11(1):10-4. PubMed ID: 26571465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postapproval drug safety.
    Abraham IL; MacDonald KM
    Health Aff (Millwood); 2006; 25(4):1186-7; author reply 1187-8. PubMed ID: 16835206
    [No Abstract]   [Full Text] [Related]  

  • 9. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 10. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation--how much can the world afford? Are we getting value for money?
    Anisfeld MH
    J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 13. Doctors and the drug industry.
    Br Med J (Clin Res Ed); 1983 Mar; 286(6368):888-9. PubMed ID: 6403120
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical prices continue to drive up supply costs.
    Hard R
    Hospitals; 1992 Mar; 66(5):49-50. PubMed ID: 1740289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Reach of the 340B Drug Pricing Program.
    Albrecht J; Mudahar S
    JAMA Dermatol; 2015 Sep; 151(9):923-4. PubMed ID: 25993384
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug safety: a contrarian's point of view.
    Cobert B
    Food Drug Law J; 2007; 62(3):501-12. PubMed ID: 17915392
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical costs and the drug industry.
    Schwartz H
    Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
    [No Abstract]   [Full Text] [Related]  

  • 18. The Use of Economic Evidence to Inform Drug Pricing Decisions in Jordan.
    Hammad EA
    Value Health; 2016; 19(2):233-8. PubMed ID: 27021758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. User-fee bill passes US Senate, but legislative hurdles remain.
    Fox JL
    Nat Biotechnol; 2007 Jun; 25(6):611. PubMed ID: 17557086
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.